Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Zeta Global Holdings Corp — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B), while Zeta Global Holdings Corp trades at $33.09 (market cap $8.29B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 7.1× Zeta Global Holdings Corp's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Zeta Global Holdings Corp for 19 Days on average.
| TAK | ZETA | |
|---|---|---|
Market Cap | $58.74B | $8.29B |
Volume | 3,110,994 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $19.05 | $33.74 |
52-Week Low | $13.23 | $14.55 |
Typical Hold Time | 1 Days | 19 Days |
Enterprise Value | $86.65B | $8.18B |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZETA trades at $33.63, down 0.33% on the day, showing resilience near its 52-week high territory. The stock maintains strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and growing AI platform adoption support the positive sentiment, though negative net income margins and elevated valuation metrics warrant caution.
The outlook remains cautiously optimistic with 75% analyst buy ratings and a $32.40 consensus target. Key opportunities include accelerating revenue growth and AI-driven customer expansion, while risks involve negative profitability, high valuation multiples, and potential insider fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
